Late onset Pneumocystis pneumonia in patients receiving rituximab for humoral renal transplant rejection

Nephrology

Volumn 14, Issue 7, 2009, Pages 696-699

  Shelton, Edward ^a   Yong, Michelle ^a   Cohney, Solomon ^a  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

Antibody mediated rejection; Infection; Pneumocystis pneumonia; Renal transplantation; Rituximab

Indexed keywords

COTRIMOXAZOLE; IMMUNOGLOBULIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; OKT 3; PREDNISOLONE; RITUXIMAB; SULFAMETHOXAZOLE; TACROLIMUS; TRIMETHOPRIM;

ADULT; ANAMNESIS; ARTICLE; BRONCHOSCOPY; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; FEMALE; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; KIDNEY GRAFT REJECTION; KIDNEY POLYCYSTIC DISEASE; PLASMAPHERESIS; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; THORAX RADIOGRAPHY;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; FEMALE; GRAFT REJECTION; HUMANS; KIDNEY TRANSPLANTATION; LYMPHOCYTES; MIDDLE AGED; PNEUMONIA, PNEUMOCYSTIS;

EID: 70349748257     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2009.01168.x     Document Type: Article

References (21)

1. Marcus R, Hagenbeek A. The therapeutic use of rituximab in non-Hodgkin's lymphoma. Eur. J. Haematol. Suppl. 2007 67 : 5-14. (Pubitemid 44934857)
2. Pescovitz MD. Rituximab, an anti-cd20 monoclonal antibody: History and mechanism of action. Am. J. Transplant. 2006 6 : 859-866.
3. Schuna AA. Rituximab for the treatment of rheumatoid arthritis. Pharmacotherapy 2007 27 : 1702-1710.
4. Sharma R, Koller L, Barclay P, Liddle C. Evaluation of the off-label usage of rituximab in a large teaching hospital in New South Wales. Intern. Med. J. 2007 37 : 569-571.
5. Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat. Rev. 2005 31 : 456-473.
6. Aksoy S, Harputluoglu H, Kilickap S et al. Rituximab-related viral infections in lymphoma patients. Leuk. Lymphoma 2007 48 : 1307-1312.
7. Vieira CA, Agarwal A, Book BK et al. Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics. Transplantation 2004 77 : 542-548.
8. Grim SA, Pham T, Thielke J et al. Infectious complications associated with the use of rituximab for ABO-incompatible and positive cross-match renal transplant recipients. Clin. Transplant. 2007 21 : 628-632.
9. McLaughlin P, Grillo-Lopez AJ, Link BK et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J. Clin. Oncol. 1998 16 : 2825-2833.
10. Davis TA, White CA, Grillo-Lopez AJ et al. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: Results of a phase II trial of rituximab. J. Clin. Oncol. 1999 17 : 1851-1857.
11. Nishio M, Fujimoto K, Yamamoto S et al. Delayed redistribution of CD27, CD40 and CD80 positive B cells and the impaired in vitro immunoglobulin production in patients with non-Hodgkin lymphoma after rituximab treatment as an adjuvant to autologous stem cell transplantation. Br. J. Haematol. 2007 137 : 349-354.
12. Kolstad A, Holte H, Fossa A, Lauritzsen GF, Gaustad P, Torfoss D. Pneumocystis jirovecii pneumonia in B-cell lymphoma patients treated with the rituximab-CHOEP-14 regimen. Haematologica 2007 92 : 139 140.
13. Ghielmini M, Schmitz SF, Cogliatti SB et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood 2004 103 : 4416 4423.
14. Venhuizen AC, Hustinx WN, van Houte AJ, Veth G, van der Griend R. Three cases of Pneumocystis jirovecii pneumonia (PCP) during first-line treatment with rituximab in combination with CHOP-14 for aggressive B-cell non-Hodgkin's lymphoma. Eur. J. Haematol. 2008 80 : 275 276.
15. Mulley WR, Hudson FJ, Skene AM et al. A single low-fixed dose of rituximab to salvage renal transplants from refractory antibody-mediated rejection. Transplantation 2009 87 : 286 289.
16. Lufft V, Kliem V, Behrend M, Pichlmayr R, Koch KM, Brunkhorst R. Incidence of Pneumocystis carinii pneumonia after renal transplantation. Impact of immunosuppression. Transplantation 1996 62 : 421 423.
17. Kasiske BL, Vazquez MA, Harmon WE et al. Recommendations for the Outpatient Surveillance of Renal Transplant Recipients. J. Am. Soc. Nephrol. 2000 11 : S1 86.
18. Gordon SM, LaRosa SP, Kalmadi S et al. Should prophylaxis for Pneumocystis carinii pneumonia in solid organ transplant recipients ever be discontinued?. Clin. Infect. Dis. 1999 28 : 240-246.
19. Green H, Paul M, Vidal L, Leibovici L. Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane Database Syst. Rev. 2007 3 : CD005590.
20. Lund FE, Schuer K, Hollifield M, Randall TD, Garvy BA. Clearance of Pneumocystis carinii in mice is dependent on B cells but not on P carinii-specific antibody. J. Immunol. 2003 171 : 1423- 1430.
21. Lund FE, Hollifield M, Schuer K, Lines JL, Randall TD, Garvy BA. B cells are required for generation of protective effector and memory CD4 cells in response to Pneumocystis lung infection. J. Immunol. 2006 176 : 6147 6154.